ReviewWorld journal of gastroenterology2021
Liver injury in the era of COVID-19.
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 69 citations in OpenAlex.
- Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.Journal of infection and public health · 2022Trial
- Possible link between steatotic liver diseases, severe COVID-19 and cognitive impairment in post-COVID-19 syndrome.Infection · 2025Article
- Pathophysiological Mechanisms Linking COVID-19 and Acute Surgical Abdomen: A Literature Review.Life (Basel, Switzerland) · 2025Review
- Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.Inflammopharmacology · 2024Review
- Spectrum of COVID-19 induced liver injury: A review report.World journal of hepatology · 2024Review
- Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?Endocrine, metabolic & immune disorders drug targets · 2024Article
- Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatology forum · 2024Review
- Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study.Frontiers in cellular and infection microbiology · 2024Article
- COVID-19 associated liver injury: An updated review on the mechanisms and management of risk groups.Liver research (Beijing, China) · 2023Review
- Relationship between hepatic and pancreatic steatosis and the COVID-19 pneumonia total severity score and prognosis with an emphasis on prognostic strengthDiagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Gastrointestinal manifestations of long-term effects after COVID-19 infection in patients with dialysis or kidney transplantation: An observational cohort study.World journal of gastroenterology · 2023Observational
- Liver manifestations in COVID-19 patients: A review article.World journal of clinical cases · 2023Review
- Gender Differences Associated with Hyper-Inflammatory Conditions in COVID-19 Patients.Aging and disease · 2023Article
- Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients.World journal of gastroenterology · 2023Review
- COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes.World journal of gastroenterology · 2023Article
- Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study.Tropical medicine and infectious disease · 2023Article
- Liver Damage Associated with SARS-CoV-2 Infection-Myth or Reality?Journal of personalized medicine · 2023Article
- COVID-19 and liver injury in individuals with obesity.World journal of gastroenterology · 2023Review
- Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023Review
- COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.World journal of virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has undoubtedly revolutionized the whole globe and given a new point of view on respiratory tract infections. Nevertheless, coronavirus disease 2019 (COVID-19) cannot be perceived as a disease limited only to pneumonia with diverse severity. More and more reports have demonstrated a wide range of possible systemic symptoms, including hepatic complications. Liver injury has been observed in a significant proportion of patients, especially in those with a severe or critical illness. COVID-19 might provoke a deterioration of liver function in patients with already diagnosed chronic liver diseases and without pre-existing liver disorders. The deterioration of liver function worsens the prognosis, increases the risk of a severe course of SARS-CoV-2 infection and prolongs the hospital stay. In general, patients who develop liver dysfunction in COVID-19 are mainly males, elderly people, and those with higher body mass index. The underlying mechanisms for hepatic failure in patients infected with SARS-CoV-2 are still unclear, nevertheless liver damage appears to be directly connected with virus-induced cytopathic effects. A liver injury observed during hospitalization might be simultaneously caused by the use of potentially hepatotoxic drugs, mainly antiviral agents. This minireview focuses on a possible relationship between COVID-19 and the liver, potential molecular mechanisms of liver damage, the characteristics of liver injury and suggested factors predisposing to hepatic manifestations in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.